Otonomy Inc (NASDAQ:OTIC) has published the clinical findings of Phase 3 clinical trials for OTIPRIO.

The publication indicated that the phase 3 trials showed positive results and they were published in the journal by JAMA Otolaryngology- Head & Neck Surgery. The drug trials were carried out in two identical phases that were sham-controlled. They were carried out on 532 pediatric subjects who were going through tympanostomy tube placement (TTP).

Eric A. Mair, the managing director of Charlotte, Eye, Ear, Nose, & Throat Associates, stated that the drug trials showcased the safety levels and efficiency towards bilateral middle ear effusion during ear tube placement in Pediatric patients. He stated that a single dose of the drug offers guaranteed compliance during treatment.

David A. Weber, the president and CEO of Otonomy expressed gratitude to the patients who contributed to the clinical trials as well as their families and physicians. He further added that the pharmaceutical company was pleased with the fact that JAMA Otolaryngology-Head & Neck Surgery decided to publish the results of the trial findings in their journal. He also stated that the company is currently working towards launching the commercialization of the drug in the US. The publication of the trial findings for OTIPRIO in a well-respected journal is expected to help to make the drug more marketable.

The 532 patients two phase 3 trials were distributed around 50 centers in Canada and the US. Pediatric patients who had bilateral middle ear effusion were chosen randomly on the day of surgery to receive tympanostomy tube placement (TTP). The primary efficacy end point was the failure of treatment due to the presence of otorrhea, missed visits through Day 15, failure of following up and the use of otic or systemic antibiotics. The trials recorded at least 3% adverse reactions to the treatment. The company offers a few warnings such as the possibility of increased microbial overgrowth.

Otonomy is a biopharmaceutical firm that is geared towards the development and sale of treatments for disorders and diseases of the ear.

Previous articleLatest Updates From TESARO Inc (NASDAQ:TSRO)
Next articleXOMA Ltd. (NASDAQ: XOMA) Gets Caution Notice for Delisting By NASDAQ LLC
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.